Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:ALKS NASDAQ:APLS NASDAQ:AXSM NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$40.06+1.1%$33.26$22.24▼$46.00$2.36B0.541.07 million shs635,510 shsALKSAlkermes$51.72-1.9%$45.76$25.17▼$55.67$8.79B0.342.32 million shs941,832 shsAPLSApellis Pharmaceuticals$41.03$34.89$16.10▼$41.14$5.25B-0.247.54 million shs68.61 million shsAXSMAxsome Therapeutics$221.64-3.6%$238.45$96.09▼$260.19$11.84B0.61.21 million shs776,378 shsZLABZai Lab$20.52+1.6%$18.66$15.96▼$41.20$2.30B0.76910,017 shs436,849 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+1.14%-1.21%+17.27%+52.38%+0.15%ALKSAlkermes-1.90%-0.29%+14.96%+54.30%+77.00%APLSApellis Pharmaceuticals0.00%0.00%0.00%+0.22%+110.73%AXSMAxsome Therapeutics-3.63%-2.91%-11.52%+21.13%+98.42%ZLABZai Lab+1.58%+4.59%+12.87%-16.04%-38.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$40.06+1.1%$33.26$22.24▼$46.00$2.36B0.541.07 million shs635,510 shsALKSAlkermes$51.72-1.9%$45.76$25.17▼$55.67$8.79B0.342.32 million shs941,832 shsAPLSApellis Pharmaceuticals$41.03$34.89$16.10▼$41.14$5.25B-0.247.54 million shs68.61 million shsAXSMAxsome Therapeutics$221.64-3.6%$238.45$96.09▼$260.19$11.84B0.61.21 million shs776,378 shsZLABZai Lab$20.52+1.6%$18.66$15.96▼$41.20$2.30B0.76910,017 shs436,849 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+1.14%-1.21%+17.27%+52.38%+0.15%ALKSAlkermes-1.90%-0.29%+14.96%+54.30%+77.00%APLSApellis Pharmaceuticals0.00%0.00%0.00%+0.22%+110.73%AXSMAxsome Therapeutics-3.63%-2.91%-11.52%+21.13%+98.42%ZLABZai Lab+1.58%+4.59%+12.87%-16.04%-38.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$42.566.23% UpsideALKSAlkermes 2.72Moderate Buy$52.501.51% UpsideAPLSApellis Pharmaceuticals 2.10Hold$36.29-11.54% DownsideAXSMAxsome Therapeutics 2.95Moderate Buy$261.4817.97% UpsideZLABZai Lab 2.71Moderate Buy$40.0094.93% UpsideCurrent Analyst Ratings BreakdownLatest AGIO, AXSM, ZLAB, APLS, and ALKS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026AXSMAxsome Therapeutics BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$310.007/20/2026ALKSAlkermes Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.00 ➝ $63.007/17/2026AXSMAxsome Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$290.007/14/2026ZLABZai Lab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/13/2026ALKSAlkermes Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$61.00 ➝ $62.007/13/2026ALKSAlkermes JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$60.007/8/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$290.007/7/2026AXSMAxsome Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$302.00 ➝ $304.007/7/2026AGIOAgios Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$28.00 ➝ $32.007/7/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $41.00(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M44.09N/AN/A$20.46 per share1.96ALKSAlkermes$1.48B5.84$1.64 per share31.49$11.02 per share4.69APLSApellis Pharmaceuticals$1.11B4.75$0.21 per share196.33$3.24 per share12.66AXSMAxsome Therapeutics$638.50M17.86N/AN/A$1.75 per share126.65ZLABZai Lab$453.28M5.15N/AN/A$6.39 per share3.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)ALKSAlkermes$241.66M$0.9057.47178.34N/A9.78%9.26%5.66%7/28/2026 (Estimated)APLSApellis Pharmaceuticals$22.39M$1.0240.23N/AN/A12.06%39.71%13.20%7/30/2026 (Estimated)AXSMAxsome Therapeutics-$183.17M-$3.73N/A54.59N/A-26.59%-267.16%-28.53%8/10/2026 (Estimated)ZLABZai Lab-$175.54M-$1.62N/AN/AN/A-39.29%-24.32%-15.52%8/6/2026 (Estimated)Latest AGIO, AXSM, ZLAB, APLS, and ALKS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026AXSMAxsome Therapeutics-$0.8919N/AN/AN/A$221.21 millionN/A8/6/2026Q2 2026ZLABZai Lab-$0.6676N/AN/AN/A$104.01 millionN/A7/30/2026Q2 2026AGIOAgios Pharmaceuticals-$1.6588N/AN/AN/A$26.07 millionN/A7/28/2026Q2 2026ALKSAlkermes-$0.04N/AN/AN/A$458.72 millionN/A5/7/2026Q1 2026APLSApellis Pharmaceuticals-$0.2888$0.15+$0.4388$0.15$208.91 million$268.30 million5/7/2026Q1 2026ZLABZai Lab-$0.5262-$0.46+$0.0662-$0.50$108.43 million$99.61 million5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AALKSAlkermesN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59ALKSAlkermes0.852.271.70APLSApellis Pharmaceuticals0.873.633.16AXSMAxsome Therapeutics2.271.391.32ZLABZai LabN/A2.402.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AALKSAlkermes95.21%APLSApellis Pharmaceuticals96.29%AXSMAxsome Therapeutics81.49%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%ALKSAlkermes4.59%APLSApellis Pharmaceuticals6.50%AXSMAxsome Therapeutics20.60%ZLABZai Lab4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableALKSAlkermes2,050166.68 million159.03 millionOptionableAPLSApellis Pharmaceuticals770128.02 million119.70 millionOptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableZLABZai Lab1,784113.78 million108.23 millionOptionableAGIO, AXSM, ZLAB, APLS, and ALKS HeadlinesRecent News About These CompaniesZai Lab (NASDAQ:ZLAB) Stock Price Up 7% - Still a Buy?July 15, 2026 | marketbeat.comZai Lab (NASDAQ:ZLAB) Sees Unusually-High Trading Volume - Should You Buy?July 13, 2026 | marketbeat.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 10, 2026 | americanbankingnews.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 10, 2026 | marketbeat.comZai Lab (NASDAQ:ZLAB) Upgraded at Zacks ResearchJuly 9, 2026 | marketbeat.comZai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 7,026 SharesJuly 2, 2026 | insidertrades.comZai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer TherapyJune 30, 2026 | finance.yahoo.comInsider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $39,529.44 in StockJune 30, 2026 | insidertrades.comZai Lab (NASDAQ:ZLAB) Director William Lis Sells 7,040 Shares of StockJune 25, 2026 | insidertrades.comZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine CarcinomasJune 16, 2026 | finance.yahoo.comPfizer, Zai Lab win China nod for cervical cancer therapy TivdakJune 9, 2026 | msn.comZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical CancerJune 8, 2026 | businesswire.comZai Lab (ZLAB) Is Down 6.0% After Leadership Shake-Up And 2026 Data Focus Has The Bull Case Changed?June 6, 2026 | finance.yahoo.comZai Lab (ZLAB) Announces Senior Leadership ChangesJune 6, 2026 | finance.yahoo.com5 Stocks That Have the Potential to Rise 1000%June 5, 2026 | insidermonkey.comZai Lab (ZLAB) Q1 2026 Earnings TranscriptJune 2, 2026 | fool.comZai Lab announces departure of president and COO Josh SmileyMay 22, 2026 | msn.comZai Lab announces departure of president and COO Josh SmileyMay 22, 2026 | msn.comZai Lab Announces Changes to Senior Leadership TeamMay 21, 2026 | businesswire.comZai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 SharesMay 16, 2026 | insidertrades.comZai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag AttachedMay 14, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGIO, AXSM, ZLAB, APLS, and ALKS Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$40.06 +0.45 (+1.14%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$40.14 +0.07 (+0.19%) As of 05:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Alkermes NASDAQ:ALKS$51.72 -1.00 (-1.90%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$51.97 +0.25 (+0.48%) As of 05:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Apellis Pharmaceuticals NASDAQ:APLSApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Axsome Therapeutics NASDAQ:AXSM$221.64 -8.36 (-3.63%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$226.08 +4.44 (+2.00%) As of 07/20/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Zai Lab NASDAQ:ZLAB$20.52 +0.32 (+1.58%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$20.58 +0.06 (+0.30%) As of 06:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Why Gold Miners Could Be the Market's Biggest Comeback Story A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Amazon’s AI Spending Is About to Face Its Most Important AWS Test Yet Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
